Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.
The principal aim of this study was to evaluate the in-vitro activity of new quinolones against clinical strains of Streptococcus pneumoniae. Four hundred and fifty-two single clinical isolates (of which 362 were susceptible to penicillin, 54 intermediate and 36 highly resistant) were tested against penicillin, cefuroxime, ciprofloxacin, levofloxacin, trovafloxacin and Bay 12-8039. Of the tested S. pneumoniae strains, 97.1 % had MICs of trovafloxacin of < or = 0.25 mg/L, and 96.7% had MICs of Bay 12-8039 of < or = 0.25 mg/L (difference not statistically significant); 81.9% of strains had MICs of cefuroxime of < or = 0.25 mg/L (P < or = 0.001 against both quinolones). Only 4% and 0.7% of the strains had MICs of levofloxacin and ciprofloxacin respectively of < or = 0.25 mg/L. Compared with older quinolones, trovafloxacin and Bay 12-8039 have good in-vitro activity against S. pneumoniae.
Weiss
K
K
Department of Infectious Diseases and Microbiology, Hôpital Maisonneuve-Rosemont, University of Montreal, Québec, Canada. weissk@microim.umontreal.ca
Laverdiere
M
M
Restieri
C
C
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009287:Naphthyridines / Q000494:pharmacology*; D011804:Quinolines; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000302:isolation & purification
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D009287:Naphthyridines; D011804:Quinolines; C080163:trovafloxacin; D000077266:Moxifloxacin